Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with placebo (very low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with phenobarbital (as active placebo) (very low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes tardive dyskinesia: No clinically important improvement compared with PLACEBO (very low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
ANXIOLYTIC ‐ BUSPIRONE may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
HERB ‐ GINKGO BILOBA probably leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (moderate certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
HORMONE ‐ MELATONIN showed no clear difference in tardive dyskinesia: No clinically important improvement compared with PLACEBO OR NO TREATMENT (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
NORADRENERGIC DRUGS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
DOPAMINERGIC DRUGS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) probably leads to lower tardive dyskinesia: 1. No clinically important improvement compared with PLACEBO (moderate certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found